Completed
PHASE2
INTERVENTIONAL
NCT01264497
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
Interventions
Name:
TH9507
Type:
DRUG
Description:
1 and 2 mg, sc daily for 12 weeks
Primary Outcomes
Measure:
Change from baseline in relative insulin response
TimeFrame:
Description:
Trial Information
NCT ID
NCT01264497
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Theratechnologies
Last Updated
December 15, 2025